Dogwood Therapeutics Inc. Common Stock (DWTX)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Dogwood as a Graham-style asset speculation, not a proven business. The company has no revenue in any filed period. Its net loss was $5.3 million in fiscal 2023, $12.3 million in fiscal 2024, and $34.3 million in fiscal 2025. In the first half of 2026, it lost $5.0 million in the quarter ended 2026-03-31 and $11.5 million in the quarter ended 2026-06-30. That is a widening cash drain, confirmed by trailing free cash flow of -$15.1 million and an FCF yield of -34.2%. The balance sheet shows no debt, with D/E of 0.00, which helps, but FairStock calculates Piotroski 0/9 and Altman Z 0.14, suggesting a fragile financial position. Business quality? Eight employees, three clinical-stage candidates, no approved product, no revenue, and thus no conventional moat. Value rests on IMC-1, Halneuron, and IMC-2 trial outcomes. On valuation, the close on 2026-10-13 was $1.30, with a market cap of $44.2 million. FairStock calculates P/B 0.64, Graham Number $9.29, and margin of safety 86.01%, which sounds deeply cheap. But those are accounting-based; the FairStock P/E of 0.69 conflicts with the negative filed earnings. Return metrics are negative: ROE -47.77%, ROCE -20.83%. Profit growth is -202.82%. Beta of 1.83 signals volatility. This is a lottery ticket tied to clinical news, not a compounding business.

In plain English: Dogwood Therapeutics is a tiny biotech with eight employees that is testing experimental medicines for pain and fatigue. It has no sales and has lost money every year, and the losses have grown recently. The stock is near its 52-week low and may look cheap on some accounting measures, but because there are no profits or revenue yet, it is a speculative company rather than a proven business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer